The placebo-controlled, crossover trial was published inJournal of Obesity and Therapeutics.It included 24 healthy adults. The primary objective was to investigate the effect of Capsimax on REE; the researchers also documented body temperature and cardiovascular markers in order to assess safety.
Related: Patent Granted to Cognitive Performance Ingredient The COVID-19 Effect on Weight Management Preliminary Research Suggests Selenium May Protect Against Obesity
The findings: Capsimax ingestion significantly increased change in REE as compared to placebo at 1, 2, and 3 hours post-dose. The change was even greater in overweight subjects at 1 and 2 hours. There were no adverse events or safety issues, but subjects did report an increased feeling of warmth.Deshanie Rai, Ph.D., VP Global Scientific & Regulatory Affairs at OmniActive, commented in a press release: "These findings are consistent with our earlier published clinical results demonstrating a benefit of Capsimax on increased metabolic rate and adds another layer of substantiation that should help consumers feel confident that Capsimax is effective either with or without a meal.”